Best Startup
At Best Startup US we track over 1,000,000 US startups and over 3 million people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United States based President operating in the Pharmaceutical space. If you think a President is missing from this list, feel free to contact our editor on editor@beststartup.us.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Ron Alfa
Senior Vice President, Translational Discovery of Recursion Pharmaceuticals
Ron Alfa is Vice President, Discovery and Product at Recursion Pharmaceuticals where he manages scientific product development and external alliances across Recursion’s AI-enabled discovery platform. Ron Alfa’s scientific contributions prior to Recursion span Neurosciences, Metabolism, and Genetics.
Follow Ron Alfa:
About Recursion Pharmaceuticals: Recursion Pharmaceuticals is a digital biology company, developing a drug discovery platform and pipeline with machine learning.
Mark Mallon
Executive Vice President, Global Product and Portfolio Strategy, Medical Affairs and Corp. Affairs of AstraZeneca
Mark Mallon is responsible for the growth and performance of AstraZeneca’s International region, which predominantly includes AstraZeneca’s commercial businesses in Asia Pacific, Russia, Latin America, the Middle East and Africa. Most recently, Mark served as Regional Vice President for Asia Pacific where he was accountable for the growth and performance of the AstraZeneca business in 14 markets. While in this role Mark has also served as President of AstraZeneca China, responsible for the company’s overall operations in China and Hong Kong. Previously, Mark led the marketing, sales and commercial operations for AstraZeneca K. K. (Japan). Since joining AstraZeneca in 1994, Mark has held a number of additional leadership roles, Including Marketing Company President of the AstraZeneca Italian subsidiary company and Vice President of Marketing and Sales Operations of AstraZeneca’s US business. While in the US, Mark also was a Board Member for the Christiana Care Network, one of the the largest healthcare networks on the East Coast. Mark received a Bachelor of Science degree in Chemical Engineering from the University of Pennsylvania and an MBA in Marketing and Finance from the Wharton School of Business. He is based in Shanghai.
Follow Mark Mallon:
About AstraZeneca, NeoGenomics: AstraZeneca is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines.
Sean Bohen
Executive Vice-President, Global Medicines Development and Chief Medical Officer of AstraZeneca
Sean was appointed Executive Vice-President, GMD in September 2015 and leads our global late-stage development organisation for both small molecules and biologics. He is also the Company’s Chief Medical Officer and is responsible for patient safety across the entire AstraZeneca and MedImmune portfolio. He joined AstraZeneca from Genentech, where he held a number of senior leadership roles across various therapy areas and was most recently Senior Vice President of Early Development. Before joining Genentech, Sean was a Clinical Instructor in Oncology at Stanford University School of Medicine, a research associate at the Howard Hughes Medical Institute and a postdoctoral fellow at the National Cancer Institute. He is a graduate of the University of Wisconsin and later earned his doctorate in biochemistry and his medical degree at the University of California, San Francisco.
Follow Sean Bohen:
About AstraZeneca: AstraZeneca is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines.
Mark Morris
Vice-President of Research and Development of Elysium
Mark Morris, Elysium Health vice president of research and development, is passionate about bringing an open source model to clinical research in an effort to accelerate advances in human health. By increasing the transparency in scientific research and developing partnerships, a multi-discipline approach may not only fast-track discovery but also lead to a more complete understanding of health issues and more effective treatments. In his role at Elysium, he is responsible for the clinical research program, product development, and commercialization of proprietary technologies. One area of particular interest is the synergy between NAD+ modulation and sirtuin activation, which can be beneficial for a wide range of therapeutic areas. Morris has fifteen years of experience developing new technologies in various industries and has received several patents throughout his career. He has a B.S. in chemical engineering from the University of Akron and resides in New York City.
Follow Mark Morris:
About Elysium: Elysium Health offers health products built with science such as dietary supplements and anti-aging drugs.
Brenton Saunders
Chairman, President and Chief Executive Officer of Allergan
Brent Saunders is Chief Executive Officer and President of Allergan plc (formerly Actavis plc). Brenton previously served as Chief Executive Officer and President of Forest Laboratories and had served as a Member of the Board of Directors at Forest since 2011. Brenton has significant healthcare industry expertise and a proven track-record leading business transformations and integrations. Prior to Forest, Brenton was Chief Executive Officer of Bausch + Lomb, a leading global eye health company, serving in this capacity from March 2010 until August 2013. Brenton also held a number of leadership positions at Schering-Plough, including the position of president of Global Consumer Health Care and was named head of integration for the company’s merger with Merck & Co. and for Schering-Plough’s acquisition of Organon BioSciences. Before joining Schering-Plough, Brenton was a Partner and Head of Compliance Business Advisory at PricewaterhouseCoopers LLP. Prior to that, Brenton was Chief Risk Officer at Coventry Health Care and Senior Vice President, Compliance, Legal and Regulatory at Home Care Corporation of America. Brenton began his career as Chief Compliance Officer for the Thomas Jefferson University Health System. Brenton serves on the Board of Trustees of the University of Pittsburgh. Brenton is also the former Chairman of the New York chapter of the American Heart Association. Brenton is a Member of the Business Council and PhRMA. Brenton earned his MBA from Temple University School of Business, his J.D. from Temple University School of Law and his Bachelor’s degree from the University of Pittsburgh.
Follow Brenton Saunders:
About Allergan, Cisco: Allergan is a global pharmaceutical company.
Raymond H. Diradoorian
Executive Vice President of Allergan
Mr. Diradoorian has been Executive Vice President, Global Technical Operations since February 2006. From April 2005 to February 2006, Mr. Diradoorian served as Senior Vice President, Global Technical Operations. Since February 2001, Mr. Diradoorian served as Vice President, Global Engineering and Technology. Mr. Diradoorian joined Allergan in July 1981. Prior to joining Allergan, Mr. Diradoorian held positions at American Hospital Supply and with the Los Angeles Dodgers baseball team. Mr. Diradoorian received a Bachelor of Science degree in Biological Sciences from the University of California, Irvine and a Master of Science degree in Technology Management from Pepperdine University.
Follow Raymond H. Diradoorian:
About Allergan: Allergan is a global pharmaceutical company.
Stephen Barat
Associate Vice President, Non-Clinical Development of Allergan
Stephen Barat is currently the Executive Director of Non-clinical and Translational Sciences – Safety Assessment and Bioanalysis for Allergan. He has 20 years of experience in global drug development and registration, with a specific interest in drug device combinations, the interface of safety assessment and CMC requirements, and extensive experience in the safety assessment of impurities. Dr. Barat is a member of the PQRI – PDP working group and toxicology sub-team as well as the USP Expert Panel for Biocompatability of Packaging Materials.
Follow Stephen Barat:
About Allergan, The Janssen Pharmaceutical Companies of Johnson & Johnson: Allergan is a global pharmaceutical company.
Joe Caltabiano
Co-Founder and President of Cresco Labs
Joseph “Joe” Caltabiano is a well-known and influential figure in the cannabis business, as well as the CEO of Choice Consolidation Corp., a special purpose acquisition company (“SPAC”) targeting an acquisition of one or more cannabis businesses or assets that can create a best-in-class cannabis multi-state operator (“MSO”). Prior to launching Choice, Caltabiano co-founded Cresco Labs, one of the most successful multi-state operators in the United States. Living and working in the Chicago metropolitan area, Caltabiano is a mentor who regularly advises both new and existing companies. His experience has covered a broad spectrum of disciplines, and he uses this diverse and extensive financial knowledge of retail, real estate, management, and the regulated cannabis sector to uncover new possibilities for investors. As a philanthropist and a childhood leukemia survivor, Caltabiano is also a significant contributor to organizations seeking a cure for cancer and supporting patients and their families.
Follow Joe Caltabiano:
About Cresco Labs: Cresco Labs is a vertically-integrated multi-state cannabis operator inciting the progressive evolution of the medical cannabis industry.
RJ Fitch
Vice President Operations & General Manager of WuXi AppTec
Innovative senior management leader Raymond J. “RJ” Fitch possesses more than two decades of experience in the biotech and global healthcare industries. As the Vice President of Operations & General Manager for WuXi AppTec Advanced Therapies, Mr. Fitch leverages his knowledge of site operations and supply chain functions to oversee logistics operations, biological testing services, engineering, and other operations at the company’s Philadelphia location. RJ Fitch is responsible for three facilities within the Philadelphia site. Mr. Fitch began his career more than 20 years ago, graduating from Philadelphia University with a bachelor of science in biology. After working for Merck & Company, he joined Sanofi Pasteur as a director of vaccine aseptic filling & formulation. He stayed with the company for seven years, rising through the ranks to become the senior director of influenza viral manufacturing. Mr. Fitch later served as the associate vice president at Genzyme, a Sanofi company, and vice president of Sanofi Pasteur in Toronto, Canada. During his time with Sanofi Pasteur, RJ Fitch returned to school to earn an executive MBA from the New York University Stern School of Business.
Follow RJ Fitch:
About WuXi AppTec: WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical.
Axel Hoos
Senior Vice President, Therapeutic Area Head of GSK
Axel Hoos oversees both its discovery and development functions and builds the Oncology portfolio of GSK across several modalities including antibodies, small molecules, bispecific molecules and cell & gene therapies. The TA’s scientific focus is on Immuno-Oncology, Epigenetics and Cell Therapy. Axel Hoos also serves on the Scientific Advisory Board of the HIV Cure Center, a co-venture of GSK and the University of North Carolina at Chapel Hill. Axel Hoos further serves as Executive Chairman of the Board of Trustees of the Sabin Vaccine Institute (SVI), a Global Health organization, Non-executive Director on the Board of Imugene, a biotech company, Co-Chairman of the Cancer Immunotherapy Consortium (CIC) and Scientific Advisory Board Member of the Cancer Research Institute (CRI). Previously, Axel Hoos was the Global Medical Lead in Immunology/Oncology at Bristol-Myers Squibb (BMS) where he developed Yervoy (Ipilimumab), the first life-extending therapy in Immuno-Oncology.
Follow Axel Hoos:
About GSK: GSK Venture Fund is a Massachusetts-based venture capital fund focused on investments within the area of bioelectronics.
Deirdre Connelly
President of North America Pharmaceuticals of GSK
Deirdre joined GSK as President, North America Pharmaceuticals, in February 2009. Prior to this, Deirdre was appointed President of US operations at Eli Lilly and Company in 2005. Previously she was Senior Vice President for Human Resources at Lilly. She had joined Lilly in 1983 as a sales representative and moved to San Juan as a marketing associate a year later. After progressing through sales and marketing roles of increasing responsibility, including Lilly’s international management development programme, she was promoted to General Manager for Eli Lilly Puerto Rico, SA, in 1995. From 1997 to 2001 she held the positions of Regional Sales Director and Executive Director of Global Marketing for Evista (an osteoporosis treatment for post-menopausal women) and was promoted to leader of the woman’s health business unit in the US affiliate. She then became Executive Director of Human Resources for the US affiliate in 2003, joining the company’s Policy Committee in 2004. A native of San Juan, Deirdre received a bachelor’s degree in economics and marketing from Lycoming College in Pennsylvania in 1983. She graduated from the Harvard University’s Advanced Management Programme in 2000, and in January 2013 was appointed to the Harvard University Public Health Policy Council. Deirdre is also a member of the Board of Directors of Macy’s Inc., the US department store chain.
Follow Deirdre Connelly:
About GSK: GSK Venture Fund is a Massachusetts-based venture capital fund focused on investments within the area of bioelectronics.
Donald Monkhouse
President of Aprecia Pharmaceuticals
Donald Monkhouse is the president and chief scientist at [Aprecia Pharmaceuticals](https://www.crunchbase.com/organization/aprecia-pharmaceuticals), a U.S.-based company that develops and manufactures precision drug delivery systems and products.
Follow Donald Monkhouse:
About Aprecia Pharmaceuticals: Aprecia Pharmaceuticals develops precision drug delivery systems and products.
Chad Clark
President of Precision for Medicine
Chad Clark is the President at Precision for Medicine.
Follow Chad Clark:
About Precision for Medicine, Precision Medicine Group: Precision for Medicine is a specialized scientific services company helping life science innovators develop medical products.
Jared Kohler
Sr. Vice President, Project Management & Data Science Operations & Precision for Medicine of Precision for Medicine
Jared Kohler is the Sr. Vice President, Project Management & Data Science Operations, Precision for Medicine at Precision for Medicine.
Follow Jared Kohler:
About Precision for Medicine, Quartz Bio: Precision for Medicine is a specialized scientific services company helping life science innovators develop medical products.
Merry Lee
Vice President, Medical Device Regulatory Strategy of Precision for Medicine
Merry Lee Bain is the Vice President, Medical Device Regulatory Strategy at Precision for Medicine.
Follow Merry Lee:
About Precision for Medicine: Precision for Medicine is a specialized scientific services company helping life science innovators develop medical products.
Zhen Li
Founder, President & CEO of ADARx Pharmaceuticals
Dr. Li is a co-founder of ADARx and a successful executive with more than two decades of diverse experience in research and development in the pharmaceutical and biotech industries. Prior to ADARx, Dr. Li served as Senior VP at Arrowhead Pharmaceuticals where she led the discovery and non-clinical development of Arrowhead’s delivery platform and multiple product candidates that are now in clinical studies. Previously, Dr. Li was a director at Merck, leading a team dedicated to siRNA development. Dr. Li received her Ph.D. in Chemistry and Chemical Biology from Harvard University, and her B.S. from Peking University.
Follow Zhen Li:
About ADARx Pharmaceuticals: ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts.
Alex Gourlay
Executive Vice President of Walgreens
Alex Gourlay joined Walgreens as Executive Vice President, President of Customer Experience and Daily Living in October 2013. In this new role, reporting to Walgreens President and Chief Executive Officer Greg Wasson, he leads an enhanced Walgreens daily living business operation overseeing customer experience, U.S. merchandising, marketing, customer insights, daily living products and promotions. Alex was previously Chief Executive, Health & Beauty Division, Alliance Boots, a role he undertook in January 2009, when he was also appointed to the Board of Alliance Boots. He had previously been Managing Director of Boots UK and a member of the Alliance Boots Group operating committee following the acquisition of Alliance Boots plc by AB Acquisitions Limited in 2007. Prior to this, he was Healthcare Director of Boots the Chemists, having held senior management positions in store operations and human resources.
Follow Alex Gourlay:
About Walgreens, Walgreens Boots Alliance: Walgreens provides multi-channel access to consumer goods and cost-effective pharmacy, health, and wellness services.
Kathleen Wilson-Thompson
Senior Vice President & Chief Human Resources Officer of Walgreens
Kathleen Wilson-Thompson is Senior Vice President & Chief Human Resources Officer at Walgreen Co.
Follow Kathleen Wilson-Thompson:
About Walgreens: Walgreens provides multi-channel access to consumer goods and cost-effective pharmacy, health, and wellness services.
Rob Ewing
Regional Vice President of Walgreens
Rob Ewing is a Regional Vice President at Walgreens.
Follow Rob Ewing:
About Walgreens: Walgreens provides multi-channel access to consumer goods and cost-effective pharmacy, health, and wellness services.
Abhi Dhar
Senior Vice President, Chief Information Officer of Walgreens
Abhi Dhar is senior vice president and chief information officer for Walgreen Co. based in Deerfield, Illinois. He is responsible for leading the information technology function and the company’s consumer-facing digital product and innovation efforts. He serves as a member of the Walgreens Enterprise Operating Committee with accountability for technology within the division. Prior to this role Dhar led the rapidly growing and award-winning mobile product/services business and simultaneously was responsible for end-to-end delivery, software development and technology innovation for the digital division within Walgreens. Dhar joined Walgreens in 2009 as group vice president and chief technology officer. Previously, he served as chief information officer (CIO) and senior vice president at TravelCLICK from 2006 to 2009, where he built a global IT and product delivery organization by restructuring the organization, recruiting top talent and optimizing vendor relationships. From 2001 to 2006, he held various top technology leadership roles with Cendant Corporation and its Travelport division. Dhar also worked in engineering and digital/online consulting capacities with PricewaterhouseCoopers and AT&T. Dhar earned an undergraduate degree in engineering from the National Institute of Engineering, Mysore University in India in 1993 and earned a master of science degree in engineering from the New Jersey Institute of Technology in 1995.
Follow Abhi Dhar:
About Walgreens: Walgreens provides multi-channel access to consumer goods and cost-effective pharmacy, health, and wellness services.
Luke Rauch
Group Vice President, Customer Experience & General Manager, Owned Brands of Walgreens
Luke Rauch is the Group Vice President, Customer Experience & General Manager, Owned Brands at Walgreens.
Follow Luke Rauch:
About Walgreens: Walgreens provides multi-channel access to consumer goods and cost-effective pharmacy, health, and wellness services.
Karen Ling
Senior Vice President & Chief Human Resources Officer of Forest Laboratories
Prior to joining Actavis, Ms. Ling served as Senior Vice President and Chief Human Resources Officer for Forest Laboratories, Inc. Ms. Ling joined Forest in January 2014 from Merck & Co., Inc., where she served as Senior Vice President, Human Resources, for the company’s Global Human Health and Consumer Care businesses worldwide. Prior to that role at Merck, she was Vice President, Compensation and Benefits. Before Merck, Ms. Ling was Group Vice President, Global Compensation & Benefits at Schering-Plough. She also spent 14 years at Wyeth in various positions of responsibility in human resources as well as in Wyeth Pharmaceutical’s Labor and Employment Department. Prior to joining Wyeth, Ms. Ling practiced corporate law with Goldstein and Manello, P.C. in Boston. Ms. Ling holds a B.A. from Yale University and a J.D. from Boston University School of Law.
Follow Karen Ling:
About Allergan, Forest Laboratories: Forest Laboratories, Inc. (NYSE: FRX) is a U.S.-based pharmaceutical company with a long track record of building partnerships.
Marco Taglietti
Executive Vice President of Forest Laboratories
Dr. Taglietti is Executive Vice President, Drug Development and Research, and Chief Medical Officer of Forest Laboratories, Inc. He continues to be President of the Forest Research Institute. He previously served as Senior Vice President—Research and Development of the Company and President, Forest Research Institute, Inc. from December 2010 to December 2013. Prior thereto, Dr. Taglietti served as Vice President—Research and Development from December 2008 to December 2010. Dr. Taglietti joined Forest in August 2007 as Executive Vice President—Research and Development and Chief Medical Officer of Forest Research Institute, Inc. Prior to joining Forest, Dr. Taglietti was Senior Vice President and Head of Global Research and Development at Stiefel Laboratories for three years. Prior to that, Dr. Taglietti was at Schering-Plough Corporation for twelve years in positions of increasing responsibility including Vice President—Worldwide Clinical Research for Anti-Infectives, Oncology, CNS, Endocrinology and Dermatology. Dr. Taglietti received his medical degree and board certifications from the University of Pavia in Italy.
Follow Marco Taglietti:
About Forest Laboratories, SCYNEXIS: Forest Laboratories, Inc. (NYSE: FRX) is a U.S.-based pharmaceutical company with a long track record of building partnerships.
Michael Scott Mann
President of Endonovo Therapeutics
Michael Scott Mann has over 30 years experience in merger and acquisitions and operational management. In 2008 Mr. Mann acquired the assets of Hanover Asset Management, now Endonovo Therapeutics, Inc,. and led the company to become listed on the OTCBB in 2012. From January 2003 to April, 2011, Mr. Mann was the Founder, President and Chief Executive Officer of U.S. Debt Settlement, Inc. (USDS), a Frankfurt listed company, where he implemented a growth by acquisition strategy successfully acquiring numerous companies. From January 2002 to July 2003, Mr. Mann was the Chief Executive Officer of Shared Vision Capital, a boutique investment banking firm that assisted emerging companies with early seed capital and bridge loans. Earlier still, from October 1998 to December 2001, Mr. Mann was the Vice President of Investor Relations for JuriSearch.com, an online legal research platform. During his tenure with JuriSearch.com, Mr. Mann was directly responsible for funding the company’s growth and development. In addition, Mr. Mann founded Universal Pacific Communications, a privately owned telecommunications company. Under his leadership as President, Universal Pacific developed a fiber optic disaster recovery telecommunications network, designed for and successfully marketed to Fortune 1000 companies.
Follow Michael Scott Mann:
About Endonovo Therapeutics: Endonovo Therapeutics is a biotechnology company developing off-the-shelf regenerative products.
Shannon Richey
Vice President & General Manager, Asterand Bioscience Detroit Operations of BioIVT
Follow Shannon Richey:
About Asterand, BioIVT: BioIVT is a worldwide provider of biological and in vitro products to pharmaceutical and biotechnology organizations
Tim Tompkins
Vice President & Deputy Chief Information Security Officer of CVSHealth
Vice President & Deputy Chief Information Security Officer at CVS Health.
Follow Tim Tompkins:
About CVSHealth: CVS Health provides an integrated healthcare services offering for its members.
David Casey
President, Board of Directors of CVSHealth
David Casey serves as Vice President, Workforce Strategies and Chief Diversity Officer for CVS Health. Casey joined the company in 2010 and is responsible for developing and driving diversity and engagement strategies across the company. He is also focused on ensuring that diversity and inclusion are embedded in CVS Health’s recruitment, talent development, performance management and succession planning efforts. In prior roles, Casey was Chief Diversity Officer at WellPoint, where he led the development and execution of enterprise-wide strategies to leverage diversity management for the workforce, workplace and marketplace. Casey was also a Regional Director of Business Development for Bernard Hodes Group, where he consulted with regional, national and international clients. Casey is a veteran of the United States Marine Corps and served in Operation Desert Storm. Casey has a Bachelor of Science degree in business administration from Indiana Wesleyan University.
Follow David Casey:
About CVSHealth: CVS Health provides an integrated healthcare services offering for its members.
Jonathan C. Roberts
President Caremark Pharmacy Services and Executive Vice President of CVS Caremark Caremark of CVSHealth
President Caremark Pharmacy Services and Executive Vice President of CVS Caremark Caremark at CVS Caremark Corporation
Follow Jonathan C. Roberts:
About CVSHealth: CVS Health provides an integrated healthcare services offering for its members.
Papatya Tankut
Vice President, Pharmacy Affairs of CVSHealth
Papatya Tankut is Vice President of Pharmacy Affairs for CVS Health. Tankut is responsible for engaging with nonprofit, governmental and health-based organizations to expand CVS Health’s efforts to improve and enhance pharmacy care. Tankut began her career as a pharmacist at CVS/pharmacy in 1994. She has held various positions within the organization, including Vice President of Pharmacy Professional Services; Director, Pharmacy Recruiting and Professional Relations; and Manager of Professional and College Relations. In those roles she helped develop the company’s pharmacist recruitment strategies and initiatives, and oversaw the regulatory compliance, quality assurance and patient safety, and retail clinical services departments. Tankut graduated from the University of Maryland School of Pharmacy.
Follow Papatya Tankut:
About CVSHealth: CVS Health provides an integrated healthcare services offering for its members.
Eileen Howard Boone
SVP of Corporate Social Responsibility & Philanthropy, President of CVS Health Foundation of CVSHealth
Eileen Howard Boone is Senior Vice President, Corporate Social Responsibility and Philanthropy, for CVS Health. In this role, she leads a team responsible for implementing the company’s philanthropic and CSR programs. Howard Boone is also President of the CVS Health Foundation, the private foundation of CVS Health. In this role, she oversees the foundation’s charitable giving and is responsible for creating and managing strategic partnerships with non-profit organizations that share in the Foundation’s commitment to provide greater access to health care in communities nationwide. Previously, she served as Senior Vice President of Corporate Communications and Community Relations for the company and led media relations, internal communications and events for ten years. During that time, one of her most significant accomplishments was establishing CVS Health All Kids Can, a signature philanthropic program committed to making life easier for children of all abilities. Prior to joining CVS Health, she gathered a wide range of executive-level experience at JP Morgan, Talbots and Office Depot. Howard Boone is a graduate of the College of the Holy Cross and received her MBA from Fordham University.
Follow Eileen Howard Boone:
About CVSHealth: CVS Health provides an integrated healthcare services offering for its members.
Stephen J. Gold
Executive Vice President & Chief Information Officer of CVSHealth
Stephen Gold is Executive Vice President and Chief Information Officer for CVS Health. In this role since July 2012, Gold is the company’s senior technology executive and has responsibility for all information systems and technology operations, including information technology strategy, application development, technology infrastructure, and business and technology operations. A seasoned executive with more than 30 years of information systems management experience, Gold was previously Senior Vice President and CIO for Avaya, guiding all aspects of the company’s technology strategy, as well as leading IT business operations and systems globally. Prior to joining Avaya, Gold was the Executive Vice President, Chief Information Officer and Corporate Chief Technology Officer for GSI Commerce. At GSI, Gold was responsible for product development, product marketing, systems architecture, product engineering and technology operations for one of the nation’s premier eCommerce solutions providers, supporting brands such as Toys R Us, Polo, BCBG, Estee Lauder, Kate Spade and all major sports leagues. Gold holds an undergraduate degree in computer science from Saint John’s University and currently serves as a member of their advisory board.
Follow Stephen J. Gold:
About CVSHealth: CVS Health provides an integrated healthcare services offering for its members.
Robert (Rocky) O. Kraft
Executive Vice President of CVSHealth
Rocky Kraft is the President at Omnicare Inc.
Follow Robert (Rocky) O. Kraft:
About CVSHealth, Omnicare, Omnicare: CVS Health provides an integrated healthcare services offering for its members.
Troyen Brennan, M.D.
Executive Vice President and Chief Medical Officer of CVSHealth
Troyen A. Brennan, M.D., M.P.H., is Executive Vice President and Chief Medical Officer of CVS Health. In this role, Brennan provides oversight for the development of CVS Health’s clinical and medical affairs and health care strategy, as well as the company’s MinuteClinic and Accordant Health Care businesses. Previously, Brennan was Chief Medical Officer of Aetna Inc., where he was responsible for clinical policies, as well as Aetna’s full range of clinical operations, disease management programs and patient management services. Prior to that, Brennan served as president and CEO of Brigham and Women’s Physicians Organization. In his academic work, he was Professor of Medicine at Harvard Medical School and Professor of Law and Public Health at Harvard School of Public Health. Brennan received his M.D. and M.P.H. degrees from Yale Medical School and his J.D. degree from Yale Law School. He has a Master’s Degree from Oxford University, where he was a Rhodes Scholar. He earned a BS from Southern Methodist University. He completed his internship and residency in internal medicine at Massachusetts General Hospital. He is a member of the Institute of Medicine of the National Academy of Sciences.
Follow Troyen Brennan, M.D.:
About CVSHealth: CVS Health provides an integrated healthcare services offering for its members.
Franklin Maddux
Chief Medical Officer and Executive Vice President for Clinical and Scientific Affairs of Fresenius Medical Care North America
Franklin W. Maddux, is the Executive Vice President for Clinical and Scientific Affairs and Chief Medical Officer of Fresenius Medical Care. Frank joined us in 2009 after Fresenius Medical Care acquired a company he founded, Health IT Services Group, a leading-edge Electronic Health Record (EHR) software company. Frank has more than 25 years of health-care experience, including the practice of nephrology. He is a founder of Specialty Care, a leading provider of perfusion and surgical support services. Frank also serves as Clinical Associate Professor of Medicine at the University of North Carolina School of Medicine and formerly practiced nephrology at the Danville (Virginia) Urologic Clinic, serving as its president from 1995 to 2005. He has served on numerous boards and committees involved in developing technology initiatives in both the medical and regional economic development arenas. He received his bachelor’s degree in mathematics from Vanderbilt and an MD degree from the University of North Carolina at Chapel Hill, where he completed his internship, residency, chief residency and nephrology fellowship.
Follow Franklin Maddux:
About Fresenius Medical Care North America: Fresenius Medical Care North America provides healthcare services to people with renal and other chronic conditions.
Rajiv Malik
President & Executive Director of Viatris
Rajiv Malik serves as the president of Viatris and on the company’s board of directors. Originally from India, Malik received a bachelor’s degree and a master’s degree in Pharmaceutical Technology from Punjab University and has 60+ process patents to his credit. Throughout his career, Malik has served in senior leadership roles as head of global regulatory affairs and head of pharma research for Ranbaxy, head of global development and registrations for Sandoz, and CEO of Matrix Laboratories Limited. During his time in this last role, Mylan acquired a controlling stake in Matrix, leading Malik on a path to handle even greater leadership responsibilities at Mylan. Since joining Mylan, Malik held roles including executive vice president, chief operating officer, and head of global technical operations. Malik was integral in developing the strategies for the company’s acquisitions such as Meda , Agila Specialties, and Merck KGaA’s generics business. Importantly, he was also intimately involved in the execution and integration of these and other acquisitions. As the president of Viatris, Rajiv’s responsibilities include overseeing day to day operations, commercial development, medical, IT, quality functions, R&D and the company’s commercial business units. He is especially suited for these varied roles given his unique leadership profile combining a global perspective on healthcare challenges as well as vast experience in scientific, commercial, and financial operations.
Follow Rajiv Malik:
About Viatris: Viatris is a global pharmaceutical company formed in 2020 through the combination of Mylan and Upjohn, a legacy division of Pfizer.
Lisa Wyman
Vice President Quality of Acceleron Pharma
Follow Lisa Wyman:
About Acceleron Pharma: Acceleron is a biopharmaceutical company engaged in developing, manufacturing and commercializing novel biotherapeutics.
Corey McCann
President and Chief Executive Officer of Pear Therapeutics
Corey M McCann M.D., Ph.D. is the President and CEO of Pear Therapeutics, a company developing prescription digital therapeutics and drug/software combinations for treatment of severe medical conditions. Previously, he was an investor with MPM Capital, where he evaluated new healthcare investment opportunities, managed relationships with strategic partners, and oversaw strategy and execution at portfolio companies. Prior to MPM, he was an Engagement Manager with McKinsey & Company, where he advised pharmaceutical, medical device, and biotechnology companies on the acquisition, development, and commercialization of life science technologies. He led McKinsey’s central nervous system (CNS) expertise group, advising clients across the healthcare value chain. Corey has previous investment experience with RiverVest Venture Partners, where he performed diligence on early stage investments, and at NeuroInsights, where he evaluated brain related technologies. Corey is also a co-founder, advisor, or Board Director at AgNovos Healthcare, Alcyone Lifesciences, Dragonfly Sciences, Edumedics, Resolute Bio, Selexys Pharmaceuticals, and Zillion Health. Dr. McCann trained as a physician-scientist via the Medical Scientist Training Program. For his PhD, he studied the molecular biology of synapses at Harvard University and at Washington University in St Louis. He was also a post-doctoral researcher at the Massachusetts General Hospital where he developed imaging techniques for the visualization of the brain. Dr. McCann received his M.D. from Washington University in St. Louis. He graduated summa cum laude from The Pennsylvania State University where he was an Evan Pugh Scholar, receiving a B.S. in Biology with minors in neuroscience, biochemistry, and molecular biology.
Follow Corey McCann:
About Pear Therapeutics: Pear Therapeutics is a software-based digital therapeutics platform designed to treat disease and enhance the efficacy of pharmaceuticals.
Chris Lento
Vice President of Commercialization of Pear Therapeutics
Follow Chris Lento:
About Pear Therapeutics: Pear Therapeutics is a software-based digital therapeutics platform designed to treat disease and enhance the efficacy of pharmaceuticals.
Jeffrey Mathers
Vice President, Commercial Technology, Software Engineering, R&D Platforms, and Architecture of Johnson & Johnson
Follow Jeffrey Mathers:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Vaibhav Narayan
Vice President, Digital Health Innovation of Johnson & Johnson
Follow Vaibhav Narayan:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Ravi Parameswar
Vice President, Head of Global Strategic Insights & Analytics of Johnson & Johnson
Follow Ravi Parameswar:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Nicholas Pachuda
Worldwide Vice President,Orthopedic Innovation,External Innovation & Enabling technologies of Johnson & Johnson
Follow Nicholas Pachuda:
About Johnson & Johnson, Peptilogics: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Amy Foley
Vice President, Product Innovation & Delivery of Johnson & Johnson
As Vice President of Product Innovation & Delivery, Amy Foley leads the Johnson & Johnson portfolio of health and wellness capabilities, including new product and service innovation, creation, implementation, operations, customer service and compliance and quality.
Follow Amy Foley:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Jane Adams
Vice President, Federal Government Affairs of Johnson & Johnson
Follow Jane Adams:
About Johnson & Johnson, Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Hartmuth Kolb
Vice President, Neuroscience Biomarkers and Janssen R&D Global Imaging of Johnson & Johnson
Follow Hartmuth Kolb:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Cat Oyler
Vice President, Global Public Health, Tuberculosis of Johnson & Johnson
Cat Oyler serves as vice-president of global public health (GPH) at Johnson & Johnson (J&J), leading the tuberculosis (TB) focus area strategy team (FAST), and as a member of the GPH executive leadership team. In this role, Cat leads the enterprise TB FAST to deliver on J&J’s aspiration to create a world without tuberculosis through ending mortality from multidrug-resistant tuberculosis. Cat previously served as global head of strategy and operations for J&J Innovation (JJI). She had responsibility for aligning the World Without Disease Accelerator, Lung Cancer Initiative, and JJI organizations to accelerate innovation in order to prevent, intercept and cure disease. Before this, Cat held the role of vice-president of strategy and external innovation for Janssen Research and Development, the global R&D arm of Janssen Pharmaceutical Companies of Johnson & Johnson. Here, she directed the development of the company’s long-term ‘A World Without Disease’ strategy, focusing on transforming human health. Additionally, Cat is an Aspen Institute First Mover Fellow and serves as executive sponsor for the university workstream for Women in Science, Technology, Engineering, Math, Manufacturing, and Design (WiSTEM2D).
Follow Cat Oyler:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Tom Heyman
President of Johnson & Johnson Development Corporation
Tom Heyman is President, Johnson & Johnson Development Corporation (JJDC), part of Johnson & Johnson Innovation. As head of JJDC, Tom will chair the board of JJDC, which represents the oldest and most reputable corporate venture fund in the life science industry. Tom will continue his position as CEO of Janssen Pharmaceutica NV in Belgium. He has been in this role since November 2008. Tom continues to be responsible for campus leadership in Beerse, Belgium, as well as the development and execution of a long-term organizational and talent strategy. Tom was appointed Chairman of the Board of Directors, Janssen Pharmaceutica in March 2012. He is a member of the Board of Directors VOKA, the Flemish Industry Association, Belgium, and a member of the Board of Directors of Innotek. As of April 2012, he is a member of the Board of Directors and the General Assembly of IMEC. Tom started his career with Johnson & Johnson in the Legal Department of Janssen Pharmaceutica NV in 1982, where he held a management position supporting legal and licensing activities. In 1990, Tom became Vice-President of Corporate Development at Ortho Pharmaceutical Corporation, and was appointed Head of Global Business Development for the Pharmaceutical Group in 1992, a position he held until March 31 2015. In his 25 years in Business Development, Tom and his Group entered into hundreds of transactions for both early and late stage Pharmaceutical products and technologies including IMBRUVUCA®, daratanumab, INVOKANA®, OLYSIO®, XARELTO®, VELCADE®, etc. He was also responsible for acquiring several key companies for J&J including Tibotec, Centocor, Cougar Pharmaceuticals, Aragon Pharmaceuticals, Covagen and Alios Biopharma. Tom has been a member of the Pharmaceuticals Group Operating Committee (GOC) from 1995 to 2015. From June 2007 until July 2009, Tom also served as Head of the CNS/IM Research & Early Development (RED) organization. He was born in the Congo, Africa, and graduated as Master of Law from the K.U. Leuven in Belgium. He continued with post-graduate studies in International Law in Geneva, Switzerland, and post-graduate studies in Business Management at the University of Antwerp in Belgium.
Follow Tom Heyman:
About Johnson & Johnson Development Corporation: Johnson & Johnson Development Corporation, a venture capital subsidiary, finances technology companies focused on patient health.
Asish Xavier
Vice President, Venture Investments of Johnson & Johnson Development Corporation
Asish Xavier is the Vice President of Venture Investments at joined Johnson & Johnson Innovation – JJDC, Inc. (JJDC) in 2004. Asish is based in Silicon Valley, California. Asish previously worked in business development at BioRexis Pharmaceutical, Inc., which was acquired by Pfizer in 2007. While at BioRexis, Asish assisted the company in raising a $30 million second round of financing. Asish has worked in business development at Structural GenomiX, Inc., acquired by Eli Lilly in 2008, and was a project leader at Message Pharmaceuticals, Inc. Asish received a Ph.D. from the University of Houston and a Master of Business Administration from the Wharton School of the University of Pennsylvania, where he graduated with honors. Asish received a Bachelor of Technology in Chemical Engineering from the Indian Institute of Technology, Kanpur, India. Asish was also a postdoctoral research Fellow in the Department of Chemistry at Johns Hopkins University.
Follow Asish Xavier:
About Cue, ESCAPE Bio, Johnson & Johnson Development Corporation, Legend Biotech, Paige, ViaCyte, XWPharma: Johnson & Johnson Development Corporation, a venture capital subsidiary, finances technology companies focused on patient health.
Marian Nakada
Vice President, Venture Investments of Johnson & Johnson Development Corporation
Marian Nakada, PhD, Vice President, Venture Investments, joined Johnson & Johnson Development Corporation (JJDC) in 2013. She is based in Boston, MA. Previously, Dr. Nakada was Vice President of Strategy & Operations and External Innovation for Johnson & Johnson’s Biotechnology CoE, where she helped drive the development and execution of the biotechnology strategy across Janssen R & D. In her role as External Innovation lead, she nurtured many productive partnerships with external partners in the biotech industry and helped build an external innovation network to complement internal research and support the execution of the Janssen R&D Biologics strategy. Dr. Nakada joined Centocor in 1990, as a scientist, performing basic research related to biologics for inflammatory and cardiovascular indications. In 2001, she took on the leadership of the newly formed Oncology Research group at Centocor. In 2007, Dr. Nakada joined the Business Development group where she participated in executing technology licenses for the Johnson & Johnson pharmaceuticals group. In that role, she identified and championed external technology opportunities to ensure that Centocor’s technologies were competitive with the industry. Dr. Nakada has authored 62 peer reviewed publications and 14 book chapters and reviews. She has a BA in Biology from Harvard College and a PhD in Pharmacology from the University of Pennsylvania.
Follow Marian Nakada:
About Johnson & Johnson Development Corporation, Women in VC: Johnson & Johnson Development Corporation, a venture capital subsidiary, finances technology companies focused on patient health.
Kadir Kadhiresan
Vice President, Venture Investments of Johnson & Johnson Development Corporation
V. Kadir Kadhiresan, PhD, joined Johnson & Johnson Innovation – JJDC, Inc. (JJDC) in 2007 and focuses on investments in medical devices and digital health. Kadir has more than two decades of operational, investment and business development experience. Based in Boston, Kadir works closely with Johnson & Johnson leadership to identify business needs and has responsibility for sourcing, investing and managing venture investment opportunities. He holds board seats for several JJDC portfolio companies. Some of his investments include Coherex Medical (Acquired by Biosense Webster/JNJ), Spinal Modulation (Acquired by St.Jude/ABT), Novocure (NASDAQ: NVCR), Torax Medical (Acquired by Ethicon/JNJ), Neotract (Acquired by Teleflex) and Inspire Medical Systems (NYSE: INSP). Before joining JJDC, Kadir was head of Business Development at Guidant, Inc., now Boston Scientific, Inc., where he led several transactions to access novel medical device technologies.
Follow Kadir Kadhiresan:
About Johnson & Johnson Development Corporation: Johnson & Johnson Development Corporation, a venture capital subsidiary, finances technology companies focused on patient health.
Stacy Feld
Vice President, Consumer Venture Investments of Johnson & Johnson Development Corporation
Stacy received a B.A. in sociology, graduating magna cum laude from the University of Pennsylvania and earned her J.D. from Vanderbilt Law School.
Follow Stacy Feld:
About Johnson & Johnson Development Corporation, Johnson & Johnson Development Corporation: Johnson & Johnson Development Corporation, a venture capital subsidiary, finances technology companies focused on patient health.
Zhi Hong
Co-founder, President, and Chief Executive Officer of Brii Biosciences
Zhi Hong, Ph.D., is Co-founder, President, and Chief Executive Officer. Prior to starting Brii Bio, Dr. Hong was Senior Vice President and Head of GlaxoSmithKline’s (GSK) Infectious Diseases Therapy Area Unit. He was widely credited as the key architect of GSK’s comeback and success in HIV & Infectious Diseases medicine discovery and development. Under his leadership, ViiV Healthcare’s (a joint venture between GSK, Pfizer, and Shionogi) HIV business was revitalized with the approval of Tivicay & Triumeq. Dr. Hong was the champion of GSK’s effort in long-acting HIV treatment & prevention therapies. He also built GSK’s efforts to cure HBV and HIV infections. GSK now has one of the most innovative pipelines against infectious diseases. Dr. Hong is a public health advocate who has helped establish multiple public-private partnerships with the U.S./E.U. governments (DTRA, BARDA, NIH & IMI) and philanthropic organizations (Gates Foundation & Wellcome Trust). In the last two years, he helped to create GSK’s Institute for Infectious Diseases and Public Health in Beijing, China. Dr. Hong started Ardea Biosciences (later acquired by AstraZeneca). He also held leadership positions at Valeant Pharmaceuticals and Schering-Plough Research Institute (now Merck). Dr. Hong has more than 25 years of experience in drug discovery and development and has brought more than 30 compounds into development, including many that have been approved and launched. He has served as a board member of Anacor Pharmaceuticals (acquired by Pfizer) and ViiV Healthcare, and also chaired the board of Qura Therapeutics.
Follow Zhi Hong:
About Brii Biosciences: Brii Biosciences is a biotechnology company that commits to bring innovative medicines to China as a way to improve public health.
Tara O’Meara
Vice President, Clinical Development Operations of Bluebird Bio
Tara O’Meara is the Vice President of Clinical Development Operations at bluebird bio. Tara oversees a team responsible for the execution and analysis of bluebird bio’s lentiviral vector based gene therapy development programs. Currently bluebird bio has 4 active programs using ex vivo gene therapy for: cerebral adrenoleukodystrophy, transfusion dependent thalassemia, sickle cell disease and multiple myeloma. bluebird’s objective is to develop and bring to market the most advanced products based on the transformative potential of gene therapy as a one-time treatment option for patients with severe genetic and rare diseases and cancer. Prior to joining bluebird, Tara ran multiple clinical trials in 2 other rare diseases, LAL Deficiency and Pompe disease. Tara served as the clinical project manager for the clinical trials that were used as the basis for the regulatory submissions that led to the approval of Myozyme™ in the United States, Europe, and more than 40 additional countries worldwide. Tara has also been responsible for everything from small Phase II trials to very large, global Phase III trials in multiple therapeutic areas, including rare inherited diseases. Tara holds a BS in biology and a minor in women’s studies from Tufts University.
Follow Tara O’Meara:
About Bluebird Bio: Bluebird Bio offers products based on the transformative potential of gene therapy for patients with genetic and orphan diseases.
Leonide Saad
Founder, President & Chief Executive Officer of Alkeus Pharmaceuticals
Dr. Saad founded Alkeus Pharmaceuticals with the goal of developing sight-saving, transformative medicines for the most serious and untreatable causes of blindness. Prior to Alkeus, he was partner in a boutique life sciences management and consulting firm in New York City, providing business and strategic guidance to biotechnology and pharmaceutical companies. He was previously at Proteus Venture Partners, an early stage, California based venture fund focused on stem cells and regenerative medicine. Dr. Saad holds a PhD focused on tissue engineering from MIT, a certificate of Financial Technology from MIT Sloan School of Management, a MS in Mechanical Engineering from MIT, a BS and MS in Applied Mathematics from University of Paris VI, and is a graduate from Ecole Polytechnique, Paris, with a concentration in organic chemistry and physics.
Follow Leonide Saad:
About Alkeus Pharmaceuticals: Alkeus Pharmaceuticals Inc., a Boston-based startup focused on treatments for serious ophthalmic conditions.
Ari Bousbib
President & CEO of IMS Health
Ari Bousbib was appointed Chief Executive Officer of IMS Health in August 2010 and was appointed to the additional role of Chairman in December 2010. Prior to IMS Health, Ari spent 14 years at United Technologies Corporation (“UTC”), a diversified company, where he most recently served as Executive Vice President of UTC and From 2008 until 2010 President of UTC’s Commercial Companies, responsible for the strategic direction and operational performance of subsidiaries Otis Elevator Company, Carrier Corporation and UTC Fire & Security. From 2002 to 2008, he served as President of Otis Elevator Company, and from 2000 to 2002 he served as its Chief Operating Officer. From 1997 to 2000, Ari was Vice President, Corporate Strategy and Development of UTC. Prior to joining UTC, Ari was a partner at Booz Allen Hamilton, a global management and technology consulting firm. Ari currently serves on the board of directors of The Home Depot, Inc., and is a member of the Harvard Medical School Health Care Policy Advisory Council. He previously served on the board of directors of Best Buy, Inc. Ari holds a Master of Science Degree in Mathematics and Mechanical Engineering from the Ecole Superieure des Travaux Publics, Paris, and an M.B.A. from Columbia University. In serving on our Board, Ari Bousbib draws from his experience with managing large, sophisticated businesses, including oversight of extensive global operations, as well as strategic, finance, supply chain and information technology matters.
Follow Ari Bousbib:
About IMS Health, IQVIA: IMS Health provides information, services and technology for the pharmaceutical and healthcare industry.
Ravi Ika
President, Founder & Chief Executive Officer of RxAdvance
A noted entrepreneur and an innovator of disruptive business solutions, Ravi Ika founded RxAdvance in 2013 and serves as president and chief executive officer of the full service pharmacy benefit management (PBM) company. He launched RxAdvance to lower pharmacy, specialty and avoidable drug-impacted medical costs and achieve better outcomes, quality and compliance in the new era of value-based health care. The RxAdvance platform Mr. Ika created from the ground up, the Collaborative PBM Cloud™, provides comprehensive automated services for all PBM administrative, clinical, specialty management, care stakeholder engagement, and compliance management functions. It does so in a way never before imagined in the PBM industry. The Collaborative PBM Cloud™ combines pharmacy, medical, and lab information to deliver actionable intelligence. Prescribers receive this real time actionable intelligence at the point of care, pharmacists at point of sale, patients via mobile cloud and payers clinical and pharmacy staff engagement through their workflows. Among the valuable results: Lower costs, optimal utilization, better outcomes, higher quality, greater transparency and rigorous compliance. Mr. Ika envisions a $750 billion PBM market long in need of transformation. The five largest PBMs, which manage over 80% of $300 billion in pharmacy benefit spend, provide limited, siloed services using antiquated, legacy platforms. Their lack of holistic vision introduces an additional $350 billion of avoidable drug-impacted medical costs into U.S. health care. In addition, $100 billion in poorly managed “buy and bill” specialty drug spend needs to be converted to an “authorize and manage” model. More than 15 years ago, Mr. Ika recognized a similar transformational opportunity in health insurance. Industry insiders, challenged to reduce administrative costs by 30% and avoidable medical costs by 20%, saw the goals as unachievable. Mired in paper-based processes, the industry also struggled with a myriad of fragmented, inflexible, and expensive legacy systems. Mr. Ika responded to this opportunity with ikaSystems, an enterprise payer-platform company. Disrupting obsolete paradigms, he delivered unprecedented change long before passage of the Patient Protection and Affordable Care Act. The ikaSystems platform decreased administrative costs for many health insurers by as much as 50% and significantly reduced avoidable medical costs. With these results, ikaSystems raised more than $140mm capital from Providence Equity and Essex Woodland Ventures. Known for building and inspiring world-class teams, Mr. Ika takes a hands-on approach to ensure his clients’ success. Over the years, healthcare industry leaders have come to rely on his vision and talent for creating enterprise platforms that radically disrupt legacy business paradigms and deliver significant value. Mr. Ika has a master’s degree in environmental engineering from Old Dominion University and worked as a research scientist at Harvard University prior to his entrepreneurial career.
Follow Ravi Ika:
About RxAdvance: RxAdvance, a national full service PBM, leverages disruptive Collaborative PBM Cloud™ to manage standard & specialty drug benefits.
Ismail Kola
Executive Vice President & President UCB NewMedicines of UCB
Dr. Kola has served as our Director since October 18, 2010. Dr. Kola currently serves as Executive Vice President of UCB S.A. in Belgium, a biopharmaceutical company dedicated to the development of innovative medicines focused on the fields of central nervous system and immunology disorders, and also serves as President of UCB New Medicines, UCB’s discovery research through proof-of-concept organization, since November 2009. Since March 2007, Dr. Kola was Senior Vice President, Discovery Research and Early Clinical Research & Experimental Medicine, and Chief Scientific Officer at Schering-Plough Corporation. Previously, Dr. Kola held senior positions commencing in 2003 at Merck & Company, where he was Senior Vice President and Site Head, Basic Research, and responsible for atherosclerosis and cardiovascular diseases, diabetes, obesity, infectious diseases, immunology and rheumatology, animal pharmacology and basic and medicinal chemistry. Prior to that, Dr. Kola was Vice President, Research, and Global Head, Genomics Science and Biotechnology, with Pharmacia Corporation, and served as consultant to SmithKline Beecham Pharmaceuticals, where he was also a member of the Genomics Advisory Board. During his tenure of proven leadership at several major pharmaceutical companies, Dr. Kola has overseen the successful development of numerous innovative new medicines, including products in the fields of diabetes, cancer, cardiovascular diseases and central nervous system disorders.
Follow Ismail Kola:
About UCB: UCB Pharma is a biopharmaceutical and specialty chemical company.
Mark McKenna
Founder, President and CEO of Prometheus Biosciences
Mark McKenna currently works as President and Chief Executive Officer at Prometheus Biosciences. He previously worked at Bausch + Lomb as Senior Vice President and General Manager.
Follow Mark McKenna:
About Prometheus Biosciences: Prometheus Biosciences develops and commercializes pharmaceutical and diagnostic products to help physicians individualize patient care.
John DeYoung
Vice President of Worldwide Business Development of Pfizer
John DeYoung is Vice President of Worldwide Business Development for Pfizer Oncology. He is a member of the Oncology Leadership Team and the Worldwide Business Development Leadership Team. John joined Pfizer in 1991 and has held leadership positions in Finance, Marketing, Commercial Development and Business Development. He received a bachelor’s degree in business from Michigan State University and an M.B.A. from the University of Chicago.
Follow John DeYoung:
About Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
Morten Sogaard
Vice President and Head, Target Sciences of Pfizer
Follow Morten Sogaard:
About Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
Andy Schmeltz
Global President & General Manager of Pfizer
Follow Andy Schmeltz:
About Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
John Young
Group President & Chief Business Officer of Pfizer
John Young is the president and general manager of Pfizer’s Primary Care Business Unit and a member of Pfizer’s Executive Leadership Team. Prior to his appointment he was the Primary Care Business Unit’s Regional President for Europe and Canada, a position he held since 2009. John has deep experience in the primary care setting, its complex and evolving customer landscape, and the development of evolved customer facing channels and capabilities. John began his 25-year career with Pfizer in 1987 as a sales representative in his native Scotland. He progressed through a number of sales and marketing management roles and was UK Sales Director from 1998 and UK Marketing Director from 2000. In 2004 he was appointed Country Manager for Australia/New Zealand, and returned to the UK as Country Manager in 2007, prior to assuming his previous role leading the Primary Care Business Unit in Europe/Canada. During his career John has also held leadership roles within local and regional industry groups, including the Association of the British Pharmaceutical Industry (ABPI) and Medicines Australia, where as Chair he led negotiations with the government to reform the country’s Pharmaceutical Benefits Scheme (PBS). Additionally, John is active in community work to serve vulnerable populations. John holds a Bachelor of Science degree in Biology from Glasgow University and an MBA from Strathclyde Graduate Business School.
Follow John Young:
About Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
Frank S Walsh
Executive Vice President of Pfizer
Frank is an accomplished Pharma and Biotech senior executive with over 20 years experience. Between 2002 and 2009, he was with Wyeth (Collegeville PA, USA), where he served as Executive Vice President and Head of Discovery Research Worldwide. This involved managing more than 1500 scientists across seven sites globally and delivering multiple products in diverse areas to IND and late stage clinical trials. Prior to joining Wyeth, Frank was at GlaxoSmithKline (UK) where he was Senior Vice President and Head of the Neurology Centre of Excellence for Drug Discovery. From 1997 to 2000, he was Vice President and Head of Neuroscience Research at SmithKline Beecham (UK). Before moving to industry, Frank had a distinguished academic career, during which he authored over 200 scientific publications. He was the Research Dean at the United Medical and Dental Schools of Guys and St. Thomas’ Hospitals (London, UK), and also the Sir William Dunn Professor of Experimental Pathology and previously worked at the Institute of Neurology Queen Square, London. He has honorary degrees from the University of Perugia, University of Bologna, University of Strathclyde and University of Dundee. He is a Fellow of King’s College London, a Fellow of the Academy of Medical Sciences London and a Corresponding Fellow of the Royal Society of Edinburgh.
Follow Frank S Walsh:
About OSSIANIX, Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
Sonal Bhatia
Vice President, North America Medical Lead of Pfizer
Follow Sonal Bhatia:
About Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
Hakan Sakul
Vice President and Head of Diagnostics of Pfizer
Follow Hakan Sakul:
About Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
Pieter Muntendam
President and CEO of SQ Innovation
Follow Pieter Muntendam:
About G3 Pharmaceuticals, SQ Innovation: SQ Innovation is a biopharmaceutical company that develops and commercializes pharmaceutical products.
Micah Bregman
Vice President, Global Strategy and Pipeline, Allergan Aesthetics of AbbVie
Micah Bregman is the Vice President, Global Strategy and Pipeline at Allergan Aesthetics, AbbVie
Follow Micah Bregman:
About AbbVie: AbbVie is a pharmaceutical company that discovers, develops, and markets both biopharmaceuticals and small molecule drugs.
Philip Hajduk
Vice President of AbbVie
Follow Philip Hajduk:
About AbbVie: AbbVie is a pharmaceutical company that discovers, develops, and markets both biopharmaceuticals and small molecule drugs.
Azita Saleki Gerhardt
Senior Vice President, Operations of AbbVie
Azita Gerhardt is the SVP and President, Operations at AbbVie.
Follow Azita Saleki Gerhardt:
About AbbVie: AbbVie is a pharmaceutical company that discovers, develops, and markets both biopharmaceuticals and small molecule drugs.
Chris Varma
Founder, President & CEO of Frontier Medicines
Chris joined Flagship in 2007 as Partner and focuses primarily on Life Science investments. He came to Flagship with significant management experience in clinical development, regulatory strategy, business development, sales, and marketing in the pharmaceutical industry. Prior to Flagship, Chris was with Novartis Pharmaceuticals since 2004 where he served most recently as Director of the Tekturna (aliskiren) marketing team responsible for all Medical Marketing, Medical Strategy, and Professional Promotions activities in the U.S. Chris also oversaw Tekturna�s extensive clinical development programs, and played a key role in the FDA approval, CMS reimbursement coverage approval, and successful commercial launch of Tekturna in early 2007. Previously at Novartis, Chris was Director of Business Development & Licensing where he identified several in-licensing opportunities and drove key transactions. Prior to that, Chris focused on corporate strategy working directly with the Novartis Pharma CEO in Basel, Switzerland. Before Novartis, Chris was a consultant for Millennium Pharmaceuticals working on special projects in the Personalized Medicine Group. Before Millennium, Chris worked for the US Food and Drug Administration (FDA) in the Office of Combination Products coordinating and managing reviews across the major Centers. Early in his career he co-founded Epitrope Corporation, a company that developed server-side solutions for wireless telecom carriers.
Follow Chris Varma:
About Frontier Medicines, Harvard Medical School, Vision Medicines: Frontier Medicines is a developer of a chemoproteomics platform intended to further accelerate the path to drug discovery.
Ramy Farid
President & CEO of Schrödinger
Ramy Farid Co-founded Nimbus Discovery, LLC. in 2009 and served as its President and also serves as its Director. Farid has been at Nimbus Therapeutics, Inc. since 2002. Prior to joining Schrödinger, Faird was an Assistant Professor at Rutgers University where his research focused on computational protein design, resulting in a number of high-profile publications. After joining Schrödinger, Farid rapidly rose through a series of leadership positions as well as led many research and development projects. He authored several highly-cited publications applying computational tools to drug discovery, including the innovative Induced-fit docking algorithm, which is the most cited article from the Journal of Medicinal Chemistry in 2006. Farid received his Ph.D. in Chemistry from Caltech in 1991, and was an NIH Postdoctoral Fellow at the University of Pennsylvania. After joining Schrödinger, Ramy rapidly rose through a series of leadership positions as well as led many research and development projects; he also authored several highly-cited publications applying computational tools to drug discovery.
Follow Ramy Farid:
About Nimbus Therapeutics, Schrödinger, Schrödinger: Schrödinger develops a chemical simulation software for use in pharmaceutical and biotechnology research.
Stephan Gotthardt
Senior Vice President Europe Supply Chain of Teva Pharmaceutical Industries
Stephan Gotthardt is the Senior Vice President Europe Supply Chain at Teva.
Follow Stephan Gotthardt:
About Teva Pharmaceutical Industries: Teva Pharmaceutical Industries is a pharmaceutical company specializing in the development, production and marketing of generic.
Parker Cassidy
Vice-President of Strategy and Business Development of Farcast
Parker leads worldwide commercial operations for Mitra Biotech, a pioneer in novel technologies to better predict personalized therapy response in oncology. Mitra’s proprietary CANScriptTM assay tests how a patient’s tumor responds to numerous therapy combinations while retaining the critical components of the tumor microenvironment, including the immune compartment and heterogeneity. Mitra has demonstrated an extremely high correlation between its in-vitro predictions and what happens in-vivo in the clinic across different tumor types and drug classes. Importantly, the company has also demonstrated that immune checkpoint inhibitors can be successfully tested on the platform. Parker works with clinicians to demonstrate CANScriptTM clinical utility, and with biopharma clients to use the system as models for patient response – speeding development of new drugs. For over 15 years, Parker has been developing and launching novel diagnostic and drug discovery products and services with companies including BD and Upstate Biotechnology (now EMD Millipore).
Follow Parker Cassidy:
About Farcast: Farcast develops a diagnostic platform that delivers powerful predictions for personalized cancer treatment selection and drug development.
Jeff Yordon
President & COO of Athenex
Jeffrey Yordon has held multiple senior management positions in the pharmaceutical industry over the last 46 years. Mr. Yordon was the Founder, Chairman and CEO of Sagent Pharmaceuticals which had a market cap of $1.6 billion when he left the company in 2015. Previous to that, Mr. Yordon was the COO of American Pharmaceutical Partners where he was a founder and the company was eventually sold to Fresenius for $5.5 billion. Mr. Yordon was the CEO of Faulding Pharmaceuticals, CEO and Founder of YorPharm, COO of Gensia Pharmaceuticals and he was instrumental in the sale of all of these companies to Apotex, Teva and Hospira for prices upwards of $3.5 billion. Mr. Yordon has successfully taken four companies public and all of the companies sold for significant returns for his shareholders. Mr. Yordon was an Ernst & Young Entrepreneur of the Year in 2011, was inducted into the Chicago Entrepreneur Hall of Fame in 2014, won a prestigious Innovation Award from the City of Chicago, was appointed to the Chicago Innovation Council in 2014, was appointed by Governor Rauner to the Illinois Sports Facilities Authority in 2015, has been appointed to be the Chairman of the Board of the Northern Illinois University Foundation, is the Chair of the NIU Political Science Advisory Panel and is actively involved in the NIU Athletic program. Mr. Yordon has three children and presides in the Chicago area.
Follow Jeff Yordon:
About Athenex, Sagent Pharmaceuticals: Athenex focuses on the development and commercialization of therapies for cancer and immunomodulatory diseases.
Jeff Bedard
President and CEO of Crown Laboratories
Jeff Bedard is the President/CEO of Crown Laboratories, Inc. Before founding Crown Laboratories, Inc. in 2000, Jeff Bedard held positions in sales and market development with Stiefel Laboratories, Inc. and Herald Pharmacal, Inc. Jeff Bedard owned a consulting firm, providing marketing and business development management advice for small to medium pharmaceutical companies. Jeff Bedard has been a Director of Crown Laboratories, Inc. since 2000 and served previously as Chairman of the Board and President. Jeff Bedard currently serves on the Boards of Northeast Tennessee State Community College Foundation, ETSU Foundation and Mountain States Foundation. He recently was inducted in the Science Hill Sports Hall of Fame. Jeff Bedard graduated with honors from University of Iowa with a degree in Chemistry.
Follow Jeff Bedard:
About Crown Laboratories: Crown Laboratories is a fully integrated specialty pharmaceutical company offering Consumer Healthcare Products.
Arthur Levin
Executive Vice President, Research & Development of Avidity Biosciences
Arthur A. Levin, Ph.D., is miRagen’s Executive Vice President of Research and Development. Dr. Levin is a drug development veteran having spent more than 30 years in the pharmaceutical industry, of which more than 15 years were in the area of research and development of RNA-targeting therapeutics. He is a recognized world expert on the preclinical and clinical development of oligonucleotide-based therapeutics. Prior to joining miRagen Therapeutics, Dr. Levin was Chief Development Officer of Santaris Pharma A/S, where he led the efforts on the first microRNA-targeting therapeutic in Phase 2 clinical trials, miravirsen. Before joining Santaris Pharma, Dr. Levin consulted for leading biotechnology companies, conducting research and development in RNA-based therapies such as mRNA, microRNA, and siRNA.Prior to consulting, Dr. Levin was Senior Vice President of Development at Isis Pharmaceuticals, where he was responsible for the drug development of Isis’ products across a range of therapeutic areas. His expertise was instrumental in advancing more than a dozen oligonucleotide drugs from basic research to clinical development in areas such as neuromuscular diseases, infectious diseases, metabolic disorders, cardiovascular disease, and cancer. He joined Isis from Hoffmann-La Roche Inc., where he was Research Leader. Dr. Levin holds a Ph.D. in Toxicology from the University of Rochester School of Medicine and Dentistry, New York, and a B.S. in Biology from Muhlenberg College.He completed his post-doctoral work at the Chemical Industry Institute of Toxicology in Research Triangle, North Carolina. He was the recipient of the Scala Award for Industrial Toxicology and is the author of more than 50 papers and book chapters.
Follow Arthur Levin:
About Avidity Biosciences, Avidity Biosciences: Avidity Biosciences is a biotech company that delivers nucleic acid therapeutics against genetic drivers of disease.
Andy Geall
Vice President of Formulations and Chemistry of Avidity Biosciences
Andy Geall is the VP of formulations and chemistry at Avidity Biosciences.
Follow Andy Geall:
About Avidity Biosciences: Avidity Biosciences is a biotech company that delivers nucleic acid therapeutics against genetic drivers of disease.
Kathryn E. Falberg
Executive Vice President and Chief Financial Officer of Jazz Pharmaceuticals
Kathryn Falberg was appointed our Executive Vice President and Chief Financial Officer in March 2012. She served as our Senior Vice President and Chief Financial Officer from 2009 to 2012. Her responsibilities include finance, strategy, corporate development and IT. From 1995 through 2001, Kathryn Falberg was with Amgen, Inc., where she served as Senior Vice President Finance, Strategy and Chief Financial Officer, and before that as Vice President, Controller and Chief Accounting Officer, and Vice President, Treasurer. From 2001 through 2008, Kathryn Falberg was President of Canyon Capital & Consulting, a private investment and consulting firm, where she worked with a number of smaller companies while also serving as a corporate director and audit committee chair for several companies. From February to November 2009, she was Chief Financial Officer and Chief Operating Officer at ARCA biopharma, Inc., a biopharmaceutical company. Kathryn Falberg received an M.B.A. and B.A. in Economics from the University of California, Los Angeles and is a Certified Public Accountant (inactive). Kathryn Falberg currently serves on the boards, and is chair of the audit committees, of biopharmaceutical companies Halozyme Therapeutics, Inc. and Medivation, Inc.
Follow Kathryn E. Falberg:
About Jazz Pharmaceuticals: Jazz Pharmaceuticals is a specialty pharmaceutical company that identifies, develops and commercializes innovative treatments.
Liang Schweizer
Co-founder, President and CEO of HiFiBiO
Liang Schweizer is the Co-founder, President and CEO of HiFiBiO Therapeutics. Previously, she co-founded Harbour Biomed and served as its CSO, successfully transforming a technology platform company to an antibody drug discovery enterprise. Before launching her entrepreneurial career, Liang served as Head of Asian Cancer Research at Sanofi, advancing Sanofi’s Asia-Pacific oncology pipeline as well as contributing to global oncology programs from preclinical to clinical efforts. Before joining Sanofi, Liang Schweizer was a director at Bristol-Myers Squibb Company, heading a group of scientists at Leads Discovery and Optimization (LDO), overseeing 60+ in vitro pharmacology projects across different therapeutic areas. Under her leadership, the team made significant contributions to 4 marketed drugs and impacted over 20 clinical candidates. She is also a co-inventor of multiple BMS Immunoncology (IO) clinical candidates. Liang Schweizer graduated from the University of Science and Technology of China (USTC) majoring in Biology. She received her Master’s degree in Microbial Engineering at the University of Minnesota with minor in Chemical Engineering. Liang earned her Ph.D. in Molecular Biology from the University in Zurich, Switzerland. Her postdoctoral training was with Dr. Harold Varmus, a Nobel Laureate, at Memorial Sloan Kettering Cancer Center (MSKCC), New York.
Follow Liang Schweizer:
About HiFiBiO: HiFiBiO provides proprietary single cell technologies for applications in drug and biomarker discovery and development.
Steven Fasman
Senior Vice President & General Counsel of Catalent Pharma Solutions
Steven Fasman is Senior VP & General Counsel at Catalent Pharma Solutions.
Follow Steven Fasman:
About Catalent Pharma Solutions, Jewish Board of Family and Children’s Services: Catalent provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies.
Barry Littlejohns
President, Advanced Delivery Technologies (ADT) of Catalent Pharma Solutions
Barry Littlejohns was named President, Advanced Delivery Technologies in July 2013. Previously, Littlejohns led Catalent’s Medication Delivery Solutions business from July 2011 to July 2013. Littlejohns has an extensive background in leading international life science businesses in both US and European organizations. He rejoins Catalent after two years as Senior Vice President of Operations and Business Development at Danish biotechnology company Genmab, where his responsibilities included strategic licensing and manufacturing oversight. Prior to Genmab, he served in a broad range of leadership roles at Catalent. These include Vice President of Global Business Operations, Vice President of Commercial Affairs for Medication Delivery Solutions, Vice President and General Manager of Injectables, and various financial, operational and leadership roles. He joined Catalent in 1989 when it was formerly the RP Scherer Corporation. Littlejohns has two degrees in business and finance from Swindon, UK.
Follow Barry Littlejohns:
About Catalent Pharma Solutions: Catalent provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies.
Christopher Anzalone
President & CEO of Arrowhead Pharmaceuticals
President & CEO at Arrowhead Research.Dr. Christopher Anzalone has been President, Chief Executive Officer and Director of the Company since December 1, 2007. In 2005, Dr. Anzalone formed and served as CEO of the Benet Group LLC, a private equity firm focused on creating and building new nano-biotechnology companies from university-generated science. Prior to his tenure at the Benet Group, he was a partner at the Washington, DC-based private equity firm Galway Partners, LLC, where he was responsible for sourcing, structuring, and building new business ventures. Prior to Galway, Dr. Anzalone was an NIH-supported post doctoral fellow in Reproductive Endocrinology at the Smithsonian Institution’s Conservation and Research Center. Dr. Anzalone holds a Ph.D. in Biology from UCLA and a B.A. in Government from Lawrence University.
Follow Christopher Anzalone:
About Arrowhead Pharmaceuticals, Galway Partners: Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.
Gerrit Klaerner
Chief Executive Officer & President of Tricida
Gerrit joined Relypsa in October 2007 after negotiating the Relypsa spin out transaction from Amgen as an advisor to the lead investor 5AM Ventures. He co-founded Ilypsa in 2003 while at Symyx Technologies. Between 2003 and 2007, Gerrit held varying positions at Ilypsa and was in charge of the series A and B financings on the company side and licensing deals with Astellas and Cubist. As Ilypsa’s Chief Business Officer, Gerrit co-led the M&A negotiations and diligence efforts. Prior to Ilypsa, he joined Symyx in 1998 as a Staff Scientist, and was later promoted to Director of Business Development. Gerrit received his Ph.D. in polymer chemistry from the Max-Planck-Institute for Polymer Research in Mainz, Germany. He conducted postdoctoral research at Stanford University and the IBM Almaden Research Center.
Follow Gerrit Klaerner:
About Tricida: Tricida operates in the healthcare industry focusing on pharmaceutical business.
Daniel Van Plew
Executive Vice President and General Manager, Industrial Operations and Product Supply of Regeneron
Daniel Van Plew has been Executive Vice President and General Manager, Industrial Operations and Product Supply since July 2007. He joined the company in July 2007 and previously served as Senior Vice President, Vice President, and General Manager, Industrial Operations and Product Supply.
Follow Daniel Van Plew:
About Regeneron: Regeneron Pharmaceuticals is a biotechnology company that invents life-transforming medicines for people with serious diseases.
Bari Kowal
Senior Vice President, Head Development Operations & Portfolio Management of Regeneron
Follow Bari Kowal:
About Regeneron: Regeneron Pharmaceuticals is a biotechnology company that invents life-transforming medicines for people with serious diseases.
Goncalo Abecasis
Vice President of Regeneron
Follow Goncalo Abecasis:
About Regeneron, University of Michigan: Regeneron Pharmaceuticals is a biotechnology company that invents life-transforming medicines for people with serious diseases.
Leonard S. Schleifer
Founder, President, and Chief Executive Officer of Regeneron
Leonard S. Schleifer, M.D., Ph.D., founded the Company in 1988, has been a Director and its President and Chief Executive Officer since its inception, and served as Chairman of the Board from 1990 through 1994. From 1984 to 1988 he was Assistant Professor at the Cornell University Medical College in the Departments of Neurology and Neurobiology. Leonard Schleifer received his M.D. and Ph.D. in Pharmacology from the University of Virginia. Leonard Schleifer is a licensed physician and is certified in neurology by the American Board of Psychiatry and Neurology.
Follow Leonard S. Schleifer:
About Regeneron: Regeneron Pharmaceuticals is a biotechnology company that invents life-transforming medicines for people with serious diseases.
Ned Braunstein
Senior Vice President, Regulatory Affairs of Regeneron
Follow Ned Braunstein:
About Regeneron: Regeneron Pharmaceuticals is a biotechnology company that invents life-transforming medicines for people with serious diseases.
Hanne Bak
Senior Vice President Preclinical Manufacturing and Process Development of Regeneron
Follow Hanne Bak:
About Regeneron: Regeneron Pharmaceuticals is a biotechnology company that invents life-transforming medicines for people with serious diseases.
David Weinreich
Executive Vice President, Head, Global Clinical Development of Regeneron
Follow David Weinreich:
About Regeneron: Regeneron Pharmaceuticals is a biotechnology company that invents life-transforming medicines for people with serious diseases.
Aris Baras
Senior Vice President, Regeneron Pharmaceuticals, General Manager, Regeneron Genetics Center of Regeneron
Aris Baras serves as Vice President and Head of the Regeneron Genetics Center (RGC), one of the largest human genetics programs in the world, spanning large-scale sequencing, informatics, and translational sciences using human genetics to advance and guide the development of Regeneron’s pipeline of important new medicines. He has established and leads several foundational genomics collaborations, such as with the Geisinger Health System to sequence at least 250,000 participants and with the UK Biobank to sequence 500,000 participants. The RGC has produced many high impact discoveries identifying new drug targets, validating existing development programs, and contributing important new gene discoveries. The RGC has sequenced more than 250,000 individuals to date, collaborating with more than 50 institutions around the world. Previously, Aris Baras held roles and responsibilities at Regeneron across R&D and business development. Prior to Regeneron, Aris Baras contributed to other biotechnology ventures and conducted research spanning antibody based therapeutics, cancer research, and nanotechnology applications in drug development. Aris Baras received his Bachelor’s of Science, M.D., and M.B.A., all from Duke University.
Follow Aris Baras:
About Regeneron: Regeneron Pharmaceuticals is a biotechnology company that invents life-transforming medicines for people with serious diseases.
George D. Yancopoulos
President, Chief Scientific Office & co-Founder of Regeneron
George D. Yancopoulos, M.D., Ph.D., joined the Company in 1989 as its Founding Scientist and is currently President, Regeneron Laboratories and Chief Scientific Officer. He received his M.D. and Ph.D. from Columbia University. Dr. Yancopoulos was the 11th most highly cited scientist in the world in the 1990s, and in 2004 he was elected to be a member of the National Academy of Sciences. Dr. Yancopoulos, together with key members of his team, is a principal inventor and developer of Regeneron’s three FDA-approved drugs – including EYLEA® (aflibercept) Injection, ZALTRAP Injection for Intravenous Infusion, and ARCALYST (rilonacept) Injection – as well as of its foundation technologies including the TRAP technology, VelociGene, and VelocImmune.
Follow George D. Yancopoulos:
About Regeneron: Regeneron Pharmaceuticals is a biotechnology company that invents life-transforming medicines for people with serious diseases.
Joseph LaRosa
Executive Vice President, General Counsel and Secretary of Regeneron
Follow Joseph LaRosa:
About Regeneron: Regeneron Pharmaceuticals is a biotechnology company that invents life-transforming medicines for people with serious diseases.
Stephen Hoge
President of Moderna Therapeutics
Stephen leads strategy, business development, and preclinical oncology for Moderna and is the inventor of several mRNA patents. Prior to Moderna, Stephen was a partner at McKinsey & Company and a leader in the firm’s Healthcare and Corporate Finance practices. At McKinsey Stephen advised senior management teams of leading biotech and pharmaceutical companies on a wide range of strategic, financial and operational issues. Prior to joining the firm, Stephen was a physician in New York. He holds an M.D. with thesis from the University of California, San Francisco, and a B.S. in Neuroscience from Amherst College.
Follow Stephen Hoge:
About Moderna Therapeutics, Onkaido Therapeutics: Moderna Therapeutics is a biotechnology company that specializes in drug discovery and drug development based on messenger RNA.
Juan Andres
Senior Vice President Technical Development, Manufacturing and Quality of Moderna Therapeutics
Follow Juan Andres:
About Moderna Therapeutics: Moderna Therapeutics is a biotechnology company that specializes in drug discovery and drug development based on messenger RNA.
Stephane Bancel
President and Founding CEO of Moderna Therapeutics
Stephane joined Flagship Ventures in 2013 and focuses on providing strategic counsel and support to portfolio companies. He is President and Founding Chief Executive Officer of Moderna Therapeutics, a Flagship VentureLabs – founded company. He is also executive chairman of the board for portfolio company BG Medicine, Inc. Stephane was previously CEO of bioMerieux, a world leader in the diagnostics industry. During his five years leading the company, he accelerated the company’s sales growth rate, enhanced its position as a global leader in clinical microbiology and re-accelerated its immunoassay franchise by focusing on high medical value biomarkers. During that time, the company’s market capitalization nearly doubled despite the financial crisis. Prior to his time at bioMerieux, Stephane was Managing Director of Eli Lilly in Belgium and Executive Director of Global Manufacturing Strategy and Supply Chain at Eli Lilly in Indianapolis. He holds a Master of Engineering from Ecole Central Paris, a Master of Science in Chemical Engineering from the University of Minnesota and an MBA from Harvard Business School. Stéphane was elected a 2009 Young Global Leader by the World Economic Forum. He was elected best CEO for Investor Relations in France in 2009 and was ranked #1 CEO in the Biotechnology sector according to the 2011 Thomson Reuters Pan European EXTEL Study.
Follow Stephane Bancel:
About Flagship Pioneering, Moderna Therapeutics, Qiagen: Moderna Therapeutics is a biotechnology company that specializes in drug discovery and drug development based on messenger RNA.
George Lloyd
Executive Vice President, Investments and General Counsel of Royalty Pharma
Follow George Lloyd:
About Royalty Pharma: Industry leader in investing in marketed and late stage biopharmaceutical products
Jim Reddoch
Chief Scientific Officer, Executive Vice President, Head of Research and Investments of Royalty Pharma
Jim Reddoch is the Chief Scientific Officer and EVP, Research & Investments, Royalty Pharma
Follow Jim Reddoch:
About Leukemia & Lymphoma Society, Memorial Sloan – Kettering Cancer Center, Royalty Pharma: Industry leader in investing in marketed and late stage biopharmaceutical products
Georgianna Harris
Vice President of Regulatory Affairs of Alkermes
Georgianna Harris leads the regulatory affairs department at Alkermes. In this role, Dr. Harris provides regulatory strategy and guidance for development candidates and commercial products. Prior to joining Alkermes, Dr. Harris spent 25 years at Merck, in positions of increasing responsibility spanning laboratory research and regulatory affairs. During her tenure with Merck’s regulatory affairs organization, Dr. Harris oversaw global development, registration and post-registration activities for multiple small-molecule and biologic medicines for obesity, bone, oncology, diabetes and women’s health indications. Dr. Harris received a Bachelor of Science degree from Boston College and a Ph.D. in biochemistry from the University of Wisconsin. She was subsequently a postdoctoral research fellow at the Massachusetts Institute of Technology, in the Department of Chemistry.
Follow Georgianna Harris:
About : Alkermes is a biotechnology company that develops, manufactures and commercializes medicines for the treatment of chronic diseases.
Mike Landine
Senior Vice President of Corporate Development of Alkermes
Mike Landine oversees Alkermes’ corporate development activities. Prior to leading corporate development, Mr. Landine served as Chief Financial Officer and Treasurer of Alkermes from March 1988 until June 1998. Mr. Landine is a member of the Board of Directors of Kopin Corporation, a publicly traded manufacturer of components for electronic products. He also previously served on the Board of Directors of GTC Biotherapeutics, a biotechnology company, from 2005 to 2010. Mr. Landine received a Bachelor of Science degree in accounting from Bentley University and is a Certified Public Accountant.
Follow Mike Landine:
About : Alkermes is a biotechnology company that develops, manufactures and commercializes medicines for the treatment of chronic diseases.
Blair Jackson
Vice President of Business Development of Alkermes
Blair Jackson leads business development at Alkermes, encompassing licensing efforts, new product evaluation and alliance management. Since joining Alkermes in 1999, Mr. Jackson has served in various roles within the company in both a scientific and corporate capacity. Mr. Jackson also serves on the board of Civitas Therapeutics, a privately held biopharmaceutical company focused on developing transformative pulmonary delivery therapies. Mr. Jackson received a Bachelor of Arts degree in biochemistry from the University of Calgary, a Bachelor of Arts in chemical engineering and a Master of Business Administration from the University of Alberta, and a Master of Science in chemical engineering practice from the Massachusetts Institute of Technology.
Follow Blair Jackson:
About : Alkermes is a biotechnology company that develops, manufactures and commercializes medicines for the treatment of chronic diseases.
